Treating patients with stool from healthy donors may sound unappealing, but this approach has proven effective against hard-to-treat infections. Ongoing research is exploring its potential for a range of other conditions. The critical role of a healthy gut microbiota is well-documented. Our intestines host around 100,000 billion bacteria and yeasts that significantly influence overall health. Disruptions in this microbiome can lead to various physical and psychological issues.
Restoring balance to this microbial community makes intuitive sense. Fecal microbiota transplantation (FMT) involves transferring stool containing a healthy microbiome from a donor to a patient. Stool banks in the United States and the Netherlands maintain supplies for such procedures.
France lacks dedicated stool banks; samples are sourced from hospitals, with donations sought as needed.
FMT has been an approved treatment in France since 2014, primarily for recurrent Clostridium difficile infections—a bacterium causing severe diarrhea and gut inflammation. When antibiotics fail, FMT offers a reliable alternative.
Donor stool undergoes rigorous screening for pathogens, parasites, and other risks. It's then homogenized, filtered, and administered after colon cleansing via enema, colonoscopy, or nasal tube.
Video of the day:"The treatment succeeds in over 90% of cases," notes Professor Harry Sokol, a gastroenterologist at Paris's Saint-Antoine Hospital. Hundreds of French patients have benefited. Trials against other antibiotic-resistant hospital-acquired bacteria show about 50% success rates, per Raymond-Poincaré Hospital in Garches.
Individuals with Crohn's disease exhibit severely depleted microbiomes, lacking key anti-inflammatory bacteria. Clinical trials using FMT are yielding positive outcomes.
At Saint-Antoine Hospital, FMT reduced corticosteroid needs: 87.5% of patients achieved remission at 10 weeks, with 57% maintaining it at six months. Long-term durability remains under study. Pilot trials for ulcerative colitis, another IBD, are also encouraging.
Diabetes and obesity may benefit too. Researchers at Saint Louis University School of Medicine (USA) demonstrated that microbiota transfer between mice altered body weight despite identical diet and activity levels.
The gut-brain axis linking microbiota to mental health is established. In depression, harmful bacteria deplete tryptophan needed for serotonin production, while dopamine-producing microbes are scarce.
FMT aims to restore balance for improved mood. Canadian trials launched in 2020 tested fecal capsules (University of Calgary) and colonoscopy-based FMT (University of Toronto).
Studies are also evaluating FMT for multiple sclerosis and autism, offering hope for these challenging conditions.
Read also: